Endothelial cell recovery between comparator polymer-based drug-eluting stents

Area of Science:

• Cardiovascular research
• Biomaterials science
• Medical device engineering

Background:

• Late stent thrombosis in coronary arteries is linked to incomplete endothelial coverage of drug-eluting stents (DES).
• Autopsy studies of U.S. Food and Drug Administration (FDA)-approved DES reveal potential healing complications.

Purpose of the Study:

• To evaluate endothelial coverage and recovery trends across various polymer-based drug-eluting stents (DES).
• To compare the healing performance of different DES designs in a preclinical model.

Main Methods:

• Rabbits were implanted with sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), zotarolimus-eluting stents (ZES), and everolimus-eluting stents (EES) for 14 or 28 days.
• Endothelial coverage was quantified using scanning electron microscopy, with assessments of platelet-endothelial cell adhesion molecule (PECAM)-1, thrombomodulin (TM), and vascular endothelial growth factor (VEGF).

Main Results:

• Everolimus-eluting stents (EES) and MULTI-LINK (ML) Vision controls demonstrated significantly higher endothelial coverage (>70%) at 14 days compared to SES, PES, and ZES (<30%).
• Poor endothelialization correlated with reduced PECAM-1 expression and increased VEGF levels at 14 days, suggesting a delayed healing response.
• No significant differences in coverage were observed among DES at 28 days, indicating catch-up healing.

Conclusions:

• This study provides the first comparative analysis of endothelial coverage in polymer-based DES.
• Disparities in arterial healing and endothelial recovery exist among different DES designs.
• Newer generation DES show a favorable healing profile compared to current FDA-approved stents.